Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan
Open Access
- 13 October 2023
- Vol. 41 (47) , 6969-6979
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health, Labour and Welfare (JPMH21HA2008)
- Japan Agency for Medical Research and Development (JP21fk0108612, JP22fk0108637)
- Nagasaki University
This publication has 30 references indexed in Scilit:
- Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in QatarNew England Journal of Medicine, 2021
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseNew England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 MonthsNew England Journal of Medicine, 2021
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) VariantNew England Journal of Medicine, 2021
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 VariantsNew England Journal of Medicine, 2021
- Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination SettingNew England Journal of Medicine, 2021
- Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020